AUPH 📈 Aurinia Pharmaceuticals - Overview
Exchange: NASDAQ • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA05156V1022
AUPH: Lupus, Kidney, Disease, Treatment, Medication
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Web URL: https://www.auriniapharma.com
Additional Sources for AUPH Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AUPH Stock Overview
| Market Cap in USD | 1,379m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 1999-01-26 |
AUPH Stock Ratings
| Growth 5y | -54.6% |
| Fundamental | -3.52% |
| Dividend | - |
| Rel. Strength Industry | -484 |
| Analysts | 4.29/5 |
| Fair Price Momentum | 7.38 USD |
| Fair Price DCF | 5.21 USD |
AUPH Dividends
No Dividends PaidAUPH Growth Ratios
| Growth Correlation 3m | 84% |
| Growth Correlation 12m | 53.2% |
| Growth Correlation 5y | -80.8% |
| CAGR 5y | -15.87% |
| CAGR/Mean DD 5y | -0.29 |
| Sharpe Ratio 12m | 0.13 |
| Alpha | -27.60 |
| Beta | 1.02 |
| Volatility | 59.26% |
| Current Volume | 1380.9k |
| Average Volume 20d | 1436.4k |
What is the price of AUPH stocks?
As of January 10, 2025, the stock is trading at USD 8.34 with a total of 1,380,864 shares traded.
Over the past week, the price has changed by -4.90%, over one month by -8.65%, over three months by +23.56% and over the past year by -7.23%.
As of January 10, 2025, the stock is trading at USD 8.34 with a total of 1,380,864 shares traded.
Over the past week, the price has changed by -4.90%, over one month by -8.65%, over three months by +23.56% and over the past year by -7.23%.
Is Aurinia Pharmaceuticals a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Aurinia Pharmaceuticals is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -3.52 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AUPH as of January 2025 is 7.38. This means that AUPH is currently overvalued and has a potential downside of -11.51%.
Neither. Based on ValueRay Fundamental Analyses, Aurinia Pharmaceuticals is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -3.52 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AUPH as of January 2025 is 7.38. This means that AUPH is currently overvalued and has a potential downside of -11.51%.
Is AUPH a buy, sell or hold?
Aurinia Pharmaceuticals has received a consensus analysts rating of 4.29. Therefor, it is recommend to buy AUPH.
Aurinia Pharmaceuticals has received a consensus analysts rating of 4.29. Therefor, it is recommend to buy AUPH.
- Strong Buy: 3
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for AUPH stock price target?
According to ValueRays Forecast Model, AUPH Aurinia Pharmaceuticals will be worth about 8.2 in January 2026. The stock is currently trading at 8.34. This means that the stock has a potential downside of -1.92%.
According to ValueRays Forecast Model, AUPH Aurinia Pharmaceuticals will be worth about 8.2 in January 2026. The stock is currently trading at 8.34. This means that the stock has a potential downside of -1.92%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 10.8 | 30% |
| Analysts Target Price | 14 | 67.9% |
| ValueRay Target Price | 8.2 | -1.9% |